Benign Liver Tumors

Know when the needle is the wrong next move

Biopsy is not the default response to a lesion with a diagnostic vascular pattern.

Percutaneous biopsy of a suspected hemangioma can cause serious hemorrhage and is generally avoided when cross-sectional imaging is characteristic.

Typical FNH is diagnosed noninvasively; biopsy is reserved for atypical lesions after expert imaging review.

Adenoma subtype can affect risk, but biopsy is considered only when imaging and clinical data leave management-changing uncertainty because sampling error and bleeding remain concerns.

If it looks like a bag of blood, do not prove it with a needle.

Three benign lesions, three different identities

Demographics and biology narrow the field before the contrast phases appear.

Hemangioma is the most common benign hepatic tumor and is a blood-filled vascular lesion, often found incidentally in middle-aged women.

FNH is a hyperplastic response to a vascular abnormality, usually in young to middle-aged women, and has no meaningful malignant potential.

Hepatic adenoma is a true hepatocellular neoplasm linked to estrogen exposure, pregnancy, obesity or metabolic syndrome, and anabolic-androgenic steroids; hemorrhage and malignant transformation drive management.

Adenoma is the benign lesion whose sex, size, and subtype most often change the plan.

Map what each lesion contains

Internal architecture explains both the imaging signature and the procedural risk.

Hemangioma consists of endothelial-lined vascular spaces separated by fibrous septa, producing very high T2 signal and blood-pool enhancement.

FNH has a central fibrous scar, radiating septa, malformed vessels, hepatocytes, and ductular reaction; functioning hepatocytes can retain hepatobiliary contrast.

Adenoma lacks normal portal tracts and bile ducts and may contain intracellular fat, sinusoidal dilatation, hemorrhage, or necrosis depending on subtype.

Size, sex, and growth move the treatment threshold

Adenoma management is risk stratification; hemangioma and FNH usually remain conservative.

In women with hepatic adenoma, withdraw estrogen exposure and address weight first; lesions at least 5 cm or still growing after an observation interval are generally treated, usually by resection when feasible.

In men, hepatic adenomas are generally resected regardless of size because malignant transformation risk is higher; known beta-catenin activation also favors resection.

Acute hemorrhage with hemodynamic instability requires resuscitation and transarterial embolization, followed by reassessment for definitive resection; ablation or embolization can be alternatives for selected nonsurgical patients.

Five centimeters is a practical adenoma threshold, not permission to ignore sex, subtype, symptoms, or growth.

Read the enhancement movie, not one still frame

Multiphasic CT or MRI turns vascular behavior into a diagnostic sequence.

A hemangioma typically begins with peripheral, discontinuous nodular enhancement and progressively fills toward the center on delayed images, paralleling the blood pool.

FNH typically enhances briskly and rather homogeneously in the arterial phase, becomes near-isointense later, and may show delayed enhancement of a central scar plus hepatobiliary contrast retention.

Adenoma commonly enhances in the arterial phase but is heterogeneous from fat, hemorrhage, or necrosis and is usually hypointense on hepatobiliary-phase MRI.

Let risk factors reveal the adenoma subtype

The name hepatic adenoma is incomplete until exposure, sex, imaging, and molecular risk are considered.

HNF1A-inactivated adenomas often contain diffuse fat and have low malignant potential; inflammatory adenomas are associated with obesity and may show persistent enhancement and an atoll sign.

Beta-catenin-activated adenomas carry greater malignant transformation risk and are associated with male sex and anabolic-androgenic steroid exposure.

Stop exogenous estrogen or anabolic steroids and pursue weight loss when relevant; then reassess size and behavior rather than assuming exposure withdrawal is definitive treatment.